Author: PathologyMCQ Editorial Team
Category: Urologic Pathology – Prostate
Last Updated: October 2026
Read Time: 18–22 minutes
Difficulty: Moderate to difficult (postgraduate pathology / residency level)

At a glance

• What it is: malignant prostatic epithelium filling and expanding pre-existing ducts and acini, with basal cells still (at least partly) present.
• How to diagnose it: markedly expanded ducts plus solid or dense cribriform growth, comedonecrosis or severe nuclear atypia, confirmed by basal cell IHC.
• Why it matters: IDC-P signals aggressive, usually high-grade cancer, must always be reported, and should not be called high-grade PIN.
• New in this update: 3 zoomable virtual slide viewers (IDC-P, basal cell cocktail, and 4 key mimics), WHO 2022 and ISUP/GUPS grading guidance, germline testing and atypical intraductal proliferation.

What is intraductal carcinoma of the prostate?

Intraductal carcinoma of the prostate (IDC-P) is a malignant epithelial proliferation that fills and expands pre-existing prostatic ducts and acini, with cytologically malignant luminal cells and a basal cell layer that is at least partly preserved.

• In most cases IDC-P is not a precursor but the intraductal spread of an existing, usually high-grade invasive carcinoma. A rare “precursor-like” form without invasive cancer exists, but it is uncommon.
• The WHO 2022 classification (5th edition, urinary and male genital tumours) keeps IDC-P as a distinct entity and stresses its strong link with high grade, high stage and poor outcome.
• It is seen in needle biopsies, TURP chips and radical prostatectomies, nearly always alongside Grade Group 4 or 5 invasive carcinoma.
• Isolated IDC-P on biopsy, without invasive cancer, is uncommon but still predicts unsampled high-grade carcinoma.

What are the essential histologic criteria for IDC-P?

Diagnosis needs markedly expanded ducts or acini containing malignant epithelium plus at least one of the following: solid or dense cribriform architecture, comedonecrosis, or severe nuclear atypia.

Criterion	What you see	Practical tip
Solid or dense cribriform growth	Tumour fills more than 50% of the duct lumen; solid sheets or tightly packed, punched-out lumina	Loose cribriform with large, irregular lumina falls short; consider atypical intraductal proliferation
Comedonecrosis	Central necrotic debris with karyorrhexis in solid, cribriform or micropapillary tumour	Distinguish from intraluminal secretions and corpora amylacea
Severe nuclear atypia	Nuclei about 6 times adjacent benign nuclei, coarse chromatin, prominent nucleoli, frequent mitoses	Enough on its own (with an expanded duct) even without necrosis or dense architecture

How does IDC-P appear on low-power and high-power microscopy?

Low-power architecture

• Markedly expanded ducts with smooth, rounded or branching outlines that follow the normal duct tree.
• Solid or dense cribriform filling, sometimes with micropapillary tufts into residual lumina.
• Several neighbouring ducts are often involved, giving a complex cribriform or solid nodule within a lobule.
• Look around: high-grade invasive carcinoma is usually nearby.

High-power cytology

• Cells resemble Gleason pattern 4 or 5 carcinoma: enlarged nuclei, irregular membranes and prominent nucleoli.
• Amphophilic to lightly eosinophilic cytoplasm.
• Frequent mitoses and apoptotic bodies, especially around comedonecrosis.

How are basal cells and immunohistochemistry used?

Basal cells are retained around IDC-P, often patchily, and are shown with p63 and high-molecular-weight cytokeratin (34βE12, CK5/6). Invasive acinar carcinoma has no basal cells.

Marker	Pattern in IDC-P	Use
p63	Nuclear staining of a continuous or patchy peripheral basal layer	Confirms the intraductal location
HMWCK (34βE12) / CK5/6	Cytoplasmic staining of the same basal cells	Usually combined with p63 and AMACR in a cocktail
AMACR	Strong cytoplasmic staining of tumour cells	Supports a malignant luminal phenotype; not specific for IDC-P
ERG	Nuclear positivity in a subset (ERG-rearranged tumours)	Concordant with the adjacent invasive carcinoma; helps show clonal relation
PTEN	Frequent loss of staining	PTEN loss is common in IDC-P and supports it over HGPIN
NKX3.1, PSA	Positive	Confirms prostatic origin (negative in urothelial carcinoma)

How is IDC-P distinguished from its mimics?

Feature	IDC-P	High-grade PIN	Invasive cribriform carcinoma	Intraductal urothelial carcinoma
Duct size	Markedly expanded	Normal to mildly enlarged	Irregular glands in stroma	Expanded
Architecture	Solid or dense cribriform, micropapillary	Tufted, micropapillary, flat, loose cribriform	Cribriform or solid	Solid nests, no true cribriform lumina
Necrosis	Comedonecrosis common	Absent	May be present (pattern 5)	May be present
Atypia	Severe, nuclei about 6× benign	Moderate, uniform	Variable to severe	Severe pleomorphism
Basal cells	Present, often patchy	Present	Absent	Present (p63 also in tumour cells)
Key IHC	NKX3.1/PSA+, AMACR+	NKX3.1+	NKX3.1/PSA+, no basal cells	GATA3+, p63+, NKX3.1/PSA−

Atypical intraductal proliferation (AIP) is the term for an intraductal lesion more atypical or complex than HGPIN (for example loose cribriform growth) that falls short of IDC-P criteria. On biopsy it warrants a comment and close follow-up, because it is often associated with nearby carcinoma.

What’s new: WHO 2022, ISUP vs GUPS, and genetics

Topic	Current guidance
Grading IDC-P with invasive cancer	The two pathology societies disagree. ISUP (2019) recommends including IDC-P in the Gleason grade of the associated invasive carcinoma. GUPS (2019) recommends not grading IDC-P and reporting it separately. WHO 2022 accepts either, provided the report says which approach was used.
Isolated IDC-P on biopsy	Report it, do not assign a Gleason grade, and add a comment that it is usually associated with high-grade carcinoma, so repeat biopsy or definitive treatment should be considered.
Cribriform pattern and IDC-P	Both should always be reported. Either finding, even in Grade Group 2, generally argues against active surveillance.
Atypical intraductal proliferation	GUPS term for intraductal lesions beyond HGPIN but short of IDC-P; report with a comment rather than as carcinoma.
Germline testing	IDC-P (and cribriform carcinoma) is enriched for germline DNA-repair gene mutations, especially BRCA2. Current guidelines advise considering germline genetic testing when IDC-P is found.
Molecular profile	PTEN loss, TP53 alterations and genomic instability are more frequent than in usual acinar carcinoma, in keeping with its aggressive behaviour.

What is the prognostic significance of IDC-P?

• IDC-P is usually seen with Grade Group 4 or 5 carcinoma and is rare with low-grade disease.
• On biopsy it predicts higher stage at prostatectomy, extraprostatic extension and seminal vesicle invasion.
• It is independently associated with biochemical recurrence, metastasis and cancer-specific death, and with poorer response to androgen deprivation therapy.
• Isolated IDC-P on biopsy should prompt repeat sampling or definitive therapy because of the high chance of unsampled aggressive cancer.

How should IDC-P be reported and staged?

• Always name “intraductal carcinoma of the prostate” in the report when present, alongside any invasive carcinoma.
• State whether IDC-P was included in the Gleason grade (ISUP approach) or reported separately (GUPS approach).
• For isolated IDC-P, add a comment on its strong association with high-grade carcinoma and the need for further sampling or treatment.
• TNM staging is based on the invasive component; IDC-P alone is not given a separate T category but is recorded as an adverse feature.

High-yield MCQs

Exam pearl and key takeaway

Exam pearl: IDC-P = markedly expanded ducts + solid/dense cribriform growth, comedonecrosis or severe atypia (nuclei about 6× benign) + retained basal cells. No basal cells means invasive cribriform carcinoma; GATA3-positive, NKX3.1-negative cells mean urothelial carcinoma.

Key takeaway: whenever IDC-P is found, alone or with invasive cancer, report it explicitly, state how it was handled in grading, and remember it should prompt consideration of germline genetic testing.

Watch the slide discussion video